Could a diabetes drug calm inflammation after heart stenting?
NCT ID NCT07292909
First seen Jan 04, 2026 · Last updated May 09, 2026 · Updated 18 times
Summary
This study tests whether empagliflozin, a diabetes drug, can reduce inflammation after a heart stent procedure. About 100 people with stable coronary artery disease scheduled for a stent will take either empagliflozin or a placebo for three days before the procedure. Researchers will measure blood markers of inflammation before and after the stent to see if the drug limits the usual inflammatory response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SGLT 2 INHIBITORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hotel Dieu de France
RECRUITINGBeirut, Beirut, 00000, Lebanon
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.